Company Overview
TAYSHA GENE THERAPIES, INC.
TSHARevenue vs. Cost of Revenue
Revenue
Cost of Revenue
Total Operating Expenses vs. Operating Income
Total Operating Expenses
Operating Income
Net Income
Net Income
Revenue
10M
2025 FY
Net Income
-109M
2025 FY
Shares Outstanding
320M
2025 FY
EPS
-0.34USD
2025 FY
Company Information
SIC Code
2836
CIK Code
1806310
Exchange
Nasdaq
Location
US